Relations between plasma von Willebrand factor or endothelin-1 and restenosis following carotid artery stenting

Med Princ Pract. 2012;21(6):538-42. doi: 10.1159/000337940. Epub 2012 May 5.

Abstract

Objective: This study was designed to investigate the relation between plasma von Willebrand factor (VWF) or endothelin-1 (ET-1) and post-carotid artery stenting (CAS) restenosis.

Materials and methods: Plasma levels of VWF and ET-1 were measured in 61 patients (36 males, mean age 64.4 ± 6.8 years) before and after CAS. The mean follow-up time was 13.8 ± 1.7 months (range, 6-63). In-stent restenosis was defined as a >10% narrowing of the vascular lumen with or without ischemic symptoms following CAS.

Results: In-stent restenosis was identified in 14 (23%) patients, including 3 with >50% restenosis. In the restenosis group, mean VWF and ET-1 levels at 2 weeks, 1 and 6 months after CAS were higher than the baseline levels (p < 0.05 or p < 0.01). Mean levels of VWF and ET-1 in the restenosis group were higher than in the non-restenosis group within 6 months after CAS (p < 0.05 or p < 0.01).

Conclusion: Persistent elevation in plasma VWF and ET-1 within the first 6 months of CAS was found in patients with in-stent restenosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Analysis of Variance
  • Biomarkers, Pharmacological
  • Coronary Restenosis / diagnosis*
  • Coronary Restenosis / drug therapy
  • Coronary Restenosis / pathology
  • Coronary Vessels / pathology*
  • Drug-Eluting Stents*
  • Endothelin-1 / blood*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis
  • Prospective Studies
  • Risk Assessment / methods
  • Stroke*
  • von Willebrand Factor*

Substances

  • Biomarkers, Pharmacological
  • Endothelin-1
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors
  • von Willebrand Factor